Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10657108 | 0.82 | ALDH1A1 (0.40) | — | |
| SCHEMBL10657113 | 0.82 | ALDH1A1 (0.40) | — | |
| SCHEMBL2064252 | 0.82 | ALDH1A1 (0.40) | — | |
| Acetic Acid SCHEMBL10662477 | 0.79 | SMN1; SMN2 (0.40) | — | |
| Acetic Acid SCHEMBL10665517 | 0.79 | SMN1; SMN2 (0.40) | — | |
| Acetic Acid SCHEMBL10658610 | 0.79 | SMN1; SMN2 (0.40) | — | |
| Acetic Acid SCHEMBL10665521 | 0.79 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL29993676 | 0.77 | POLB (0.42) | POLBSLC22A1PRCPGBA1HDAC8 | |
| SCHEMBL10939122 | 0.72 | SLC22A1 (0.42) | POLBSLC22A1PRCPGBA1ADRB2 | |
| SCHEMBL8951753 | 0.70 | ALDH1A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104761496-B | Synthesis method of dextromethorphan intermediate | 华东理工大学 | 2017-05-24 | — | — | CN | disclosed |
| CN-104761496-A | Synthesis method of dextromethorphan intermediate | UNIV EAST CHINA SCIENCE & TECH | 2015-07-08 | — | — | CN | disclosed |
| US-20070281957-A1 | Crystalline Forms of Levorphanol | MALLINCKRODT INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-5512577-A | Bicyclic hexahydroaporphine and 1-benzyloctahydroisoquinoline therapeutic compositions and processes for utilizing said compositions | CREIGHTON UNIVERSITY (US) | 1996-04-30 | — | — | US | disclosed |
| US-5512577-A | Bicyclic hexahydroaporphine and 1-benzyloctahydroisoquinoline therapeutic compositions and processes for utilizing said compositions | CREIGHTON UNIVERSITY (US) | 1996-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281957-A1 | Crystalline Forms of Levorphanol | OPRL1, OPRK1, AVPR2 | POLB 4235/4885SLC22A1 598/4885PRCP 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.